Neurodegenerative disorders are spreading worldwide and are one of the greatest threats to
public health. There is currently no adequate therapy for these disorders, and therefore there …

Precision oncology benefits from effective early phase drug discovery decisions. Recently,
drugging inactive protein conformations has shown impressive successes, raising the …

Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine kinase and an attractive
therapeutic target for Alzheimer's disease. Based on proteolysis-targeting chimera …

Inhibiting glycogen synthase kinase 3 (GSK3) improves muscle function, metabolism, and
bone health in many diseases and conditions; however, whether GSK3 should be targeted …

Glial fibrillary acidic protein (GFAP) is an intermediate filament structural protein involved in
cytoskeleton assembly and integrity, expressed in high abundance in activated glial cells …

Chronic, low-grade inflammation has been implicated in aging and age-dependent
conditions, including Alzheimer's disease, cardiomyopathy, and cancer. One of the age …

Kinases have proven valuable targets in successful cancer drug discovery projects, but not
yet for malignant brain tumors where type-II inhibition of cyclin-dependent kinase 5 (CDK5) …

Glycogen synthase kinase‐3β (GSK‐3β) is a target enzyme considered for the treatment of
multiple human diseases, from neurodegenerative pathologies to viral infections and …

Homozygosity for the ε4 allele of APOE increases the odds of developing Alzheimer's by 12
to 15 times relative to the most common ε3; ε3 genotype, and its association with higher …

Protein homeostasis, the balance between protein synthesis and degradation, requires the
clearance of misfolded and aggregated proteins and is therefore considered to be an …